Welcome to the Utah Chapter of the American College of Cardiology
|
Ed Miner, MD, FACC Utah, Chapter President ACC Governor, Utah |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!. For more information and to register, please visit:
ACC Rockies Chapter Meeting 2025
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- SURMOUNT-MAINTAIN: Continuing Tirzepatide Maintains Weight LossIn patients with obesity, continuing tirzepatide at either the maximum tolerated dose (MTD) of 10 or 15 mg or a reduced dose of 5 mg was safe and effectively maintained weight loss along with its associated health benefits, compared to switching to placebo, according to results from the SURMOUNT-MAINTAIN trial published May 12 in The […]
- ACC CardiaCast: In Case You Missed It: ACC.26 ATTR-CM Treatment UpdatesThis CardiaCast episode explores the latest advances in transthyretin amyloid cardiomyopathy (ATTR-CM) presented at ACC.26, with a focused review of newly released late-stage clinical trial data for currently available disease-modifying therapies.
- Did Disparities in ICD Implantations Worsen During the COVID-19 Pandemic? | NCDR StudyThe incidence of ICD implantations declined significantly during the COVID-19 pandemic, according to a recent study published in Heart Rhythm. Although disparities by sex, race and ethnicity persisted during peak COVID, they did not worsen.
- AFib Ablation Approaches Differ by Hospital Teaching Status | NCDR StudyProcedural approaches for atrial fibrillation (AFib) ablation differ by hospital teaching status; however, overall complication rates are similar, according to a recent study published in JAHA.
- ACC CardiaCast: The Evolving Role of PCSK9 Inhibitors in LDL-C ManagementIn this episode of CardiaCast, Dr. Michael Blaha will be joined by Dr. Ann Marie Navar to discuss the 2026 updates to ACC/AHA guideline on management of dyslipidemia and key clinical trial data supporting the use of PCSK9 inhibitors in getting patients to their lipid goals.